Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives
Jennifer A Flegg, Philippe J Guerin, Francois Nosten, Elizabeth A Ashley, Aung Pyae Phyo, Arjen M Dondorp, Rick M Fairhurst, Duong Socheat, Steffen Borrmann, Anders Bjorkman, Andreas Martensson, Mayfong Mayxay, Paul N Newton, Delia Bethell, Youry Se, Harald Noedl, Mahamadou Diakite, Abdoulaye A Djimde, Tran T Hien, Nicholas J White Show all
MALARIA JOURNAL | BMC | Published : 2013
BACKGROUND: The emergence of Plasmodium falciparum resistance to artemisinins in Southeast Asia threatens the control of malaria worldwide. The pharmacodynamic hallmark of artemisinin derivatives is rapid parasite clearance (a short parasite half-life), therefore, the in vivo phenotype of slow clearance defines the reduced susceptibility to the drug. Measurement of parasite counts every six hours during the first three days after treatment have been recommended to measure the parasite clearance half-life, but it remains unclear whether simpler sampling intervals and frequencies might also be sufficient to reliably estimate this parameter. METHODS: A total of 2,746 parasite density-time profi..View full abstract
This study was supported by the Bill and Melinda Gates Foundation and in part by the Intramural Research Program of the NIAID, NIH. Francois Nosten, Elizabeth Ashley, Aung Pyae Phyo, Arjen M, Mayfong Mayxay, Paul N Newton, Tran Tinh Hien, and Nicholas J White are all supported by the Wellcome Trust. All clinical studies were approved by the respective ethics committees or institutional review boards of each collaborative entity and host country of conduct. All subjects provided informed consent before study participation, and parents or legal guardians provided informed consent on behalf of their children.